Methods of using HSV-2 single cycle virus delta-gD and HSV-2 recombinant glycoprotein D
AssigneeAlbert Einstein College of Medicine
InventorsBetsy C. Herold, Clare Burn Aschner
Life of this patent
Estimating the term…
Abstract
Methods of vaccinating, immunizing and/or treating a subject against a herpes simplex virus infection or a disease caused by a herpes simplex virus infection comprise administering to the subject an effective amount of a HSV-2 single-cycle virus and an effective amount of a recombinant HSV-2 glycoprotein D, wherein the HSV-2 single-cycle virus comprises HSV-2 having a deletion of glycoprotein D-encoding gene in the genome and the HSV-2 is phenotypically complemented with an HSV-1 glycoprotein D on a lipid bilayer of the HSV-2.
Claims30
A method of vaccinating a subject against a herpes simplex virus-2 (HSV-2) infection or a disease caused by an HSV-2 infection comprising administering to the subject an effective amount of a HSV-2 single-cycle virus and an effective amount of a recombinant HSV-2 glycoprotein D (rgD-2) to vaccinate the subject for the HSV-2 infection or the disease caused by the HSV-2 infection or the disease caused by the HSV-2 infection,
- wherein the HSV-2 single-cycle virus comprises a genome having a deletion of glycoprotein D-encoding gene (gD-2) and said HSV-2 single-cycle virus is phenotypically complemented with an HSV-1 glycoprotein D (gD-1) on a lipid bilayer of said HSV-2 single-cycle virus.
A method of immunizing a subject against a herpes simplex virus-2 (HSV-2) infection or a disease caused by an HSV-2 infection comprising administering to the subject an effective amount of an HSV-2 single-cycle virus and an effective amount of a recombinant HSV-2 glycoprotein D (gD-2) to immunize the subject for the HSV-2 infection or the disease caused by the HSV-2 infection,
- wherein the HSV-2 single-cycle virus comprises genome having a deletion of glycoprotein D-encoding gene (gD-2) and said HSV-2 single-cycle virus is phenotypically complemented with an HSV-1 glycoprotein D (gD-1) on a lipid bilayer of said HSV-2 single-cycle virus.
A method of treating or inhibiting a herpes simplex virus-2 (HSV-2) infection in a subject or treating or inhibiting a disease caused by an HSV-2 infection in a subject, comprising administering to the subject an effective amount of an HSV-2 single-cycle virus and an effective amount of a recombinant HSV-2 glycoprotein D (gD-2) to treat or prevent the HSV-2 infection in the subject or the disease caused by the HSV-2 infection in the subject,
- wherein the HSV-2 single-cycle virus comprises a genome having a deletion of glycoprotein D-encoding gene (gD-2) and said HSV-2 single-cycle virus is phenotypically complemented with an HSV-1 glycoprotein D (gD-1) on a lipid bilayer of said HSV-2 single-cycle virus.
Dependencies are inferred from the claim text.